|
Diprolene The stability of betamethasone-17-valerate in semi-solid bases.
Yip YW, Po LW.
The stability of betamethasone-17-valerate in semi-solid bases has been investigated. Emphasis has been placed on the stability problems which could arise upon dilution of proprietary preparations by the use of model systems. Betamethasone-17-valerate has been shown to decompose to betamethasone-21-valerate and betamethasone alcohol. Quantitation of the decomposition was by direct densitometry on thin layer chromatographic plates. The decomposition was found to be an apparent first order process and to depend on the diluent used and its concentration. Attempts were also made to relate the rate of decomposition to the pH of the base used, and to stabilize the products.
Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39141&dopt=Abstract betamethasone Diprolene AF
Diprolene The effects of antenatal betamethasone administration on fetal heart rate and behaviour depend on gestational age.
Mulder EJ, Koenen SV, Blom I, Visser GH.
Department of Perinatology and Gynaecology, Wilhelmina Children's Hospital, University Medical Centre, KE.04.123.1, Lundlaan 6, 3584 EA Utrecht, The Netherlands. emulder azu.nl
OBJECTIVE: We previously reported decreases in fetal heart rate (FHR) variability and body and breathing movements after maternal betamethasone administration. We now test the hypothesis that fetal responsiveness to betamethasone depends on the gestational age at which glucocorticoid therapy is started. DESIGN OF THE STUDY: 1-h recordings of FHR (n=350) and fetal movements (n=310) made during a 5-day period (days 0-4) were available for analysis. The recordings had been obtained from 63 pregnant women at high risk for preterm delivery who received betamethasone (two doses of 12 mg 24 h apart) between 26 and 34 weeks' gestational age (wGA). The response to betamethasone, i.e. the direction and magnitude of change in FHR and movement parameters compared with baseline (day 0), was studied in relation to gestational age at drug administration. RESULTS: Fetuses exposed to betamethasone at 29-34 wGA showed a decrease in FHR on day 1 (indicative of baroreceptor reflex), and reduced breathing activity and prolonged episodes of quiescence with a concomitant decrease in body movements on days 1 and 2. However, these changes were not observed if betamethasone administration occurred at 26-28 wGA. Betamethasone-induced reductions in FHR variability were similar in young and older fetuses. CONCLUSIONS: Age-related differential responsiveness to betamethasone was found for all studied fetal processes (body and breathing movements, FHR, and quiescence), except FHR variability. Our results suggest ontogenic changes in the mechanisms presumed to underlie these processes (glucocorticoid receptor (GR) maturation, cardiovascular and neuro-endocrine development).
Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14729164&dopt=Abstract betamethasone Diprolene AF
Diprolene Cytokine profile in paranasal effusions in patients with chronic sinusitis using the YAMIK sinus catheter with and without betamethasone.
Furukido K, Takeno S, Ueda T, Yajin K.
Department of Otorhinolaryngology, Hiroshima University School of Medicine, Kasumi 1-2-3, Minami-ku, 734-8551, Hiroshima, Japan, furukido hotmail.com.
Recently, the YAMIK sinus catheter (YAMIK) has been reported to be a useful therapeutic device in the treatment of sinusitis. The present study was conducted to compare its delivery of either a normal saline (NS) or a betamethasone solution (0.4 mg/ml) into the paranasal sinuses of 25 patients (39 sides) with chronic sinusitis. The following parameters were evaluated: (1) subjective nasal clinical symptoms (nasal discharge, nasal obstruction, postnasal drip and headache), (2) X-ray photographs (ethmoid and maxillary sinuses) and (3) cytokine levels (IL-1beta, IL-8 and TNF-alpha) by enzyme-linked immunosorbent assay. The total nasal symptom scores significantly decreased after the first therapy, and the total X-ray photograph scores significantly decreased after therapy with either NS or the betamethasone solution. In both NS and betamethasone patients, the levels of IL-1beta and IL-8 had significantly decreased by the 3rd and 2nd weeks after therapy, respectively. In contrast, the TNF-alpha level decreased after the first therapy with betamethasone solution and remained unchanged after therapy with NS. These findings suggest that evacuation of the pathological effusions in sinuses may exert a beneficial effect by reducing the levels of IL-1beta and IL-8, and we speculate that removal of pathological effusions from the sinuses may provide treatment through different mechanisms than those that occur in treatment with betamethasone.
Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14963719&dopt=Abstract betamethasone Diprolene AF
Diprolene [Pituitary adrenocortical response to high dose administration of betamethasone in neurosurgical patients (author's transl)]
[Article in Japanese]
Ohkubo T, Kubo O, Jimbo M, Kitamura K, Demura H, Demura R, Shizume K.
Using RIA technique, response patterns of ACTH-adrenocortical system to short term large dose corticosteroid therapy for neurosurgical patients were investigated. The subjects were consisted of 20 males and 13 females, ageing ranging from 10 to 60 years old. The subjects were divided into three groups according to mode of steroid administration. In the first group, 12 mg/day of betamethasone were administered for 5 days and cancelled without gradual reduction. In the second group, 12 mg/day of betamethasone were administered for 4 days and 6 mg/day of betamethasone were given for following 2 days. In the third group, 12 mg/day of betamethasone were administered for 3 days and gradual reduction of betamethasone was given for following 4-5 days. Response of plasma cortisol level to synthetic 18-ACTH were measured in all patients for 3 days after betamethasone administration cancelled. The results led to the following conclusion. 1) The second and third groups had not any clinical symptom after steroid cancelled, but one half cases of the first group had mild headache, nausea for 2 days after cancelled. 2) Recovery process of adrenocortical function in the second group is most rapidly, compared with that in other two groups. 3) In the postoperative steroid therapy in neurosurgery, it could be concluded that 4 days massive administration of steroid followed by stepwise reduction in 2 days would be functionally well tolerated by adrenocortical system.
Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6257262&dopt=Abstract betamethasone Diprolene AF
Diprolene Antenatal betamethasone changes cord blood monocyte responses to endotoxin in preterm lambs.
Kramer BW, Ikegami M, Moss TJ, Nitsos I, Newnham JP, Jobe AH.
University Children's Hospital, 97080 Wurzburg, Germany. kramer_b kinderklinik.uni.wurgburg.de
Corticosteroids are routinely administered to women at risk for preterm delivery to induce fetal lung maturation. Antenatal corticosteroids have immunomodulatory effects on fetal immune cells that are poorly understood. We hypothesized that maternal betamethasone would alter in fetal monocytes both the initiation of inflammation in response to pro-inflammatory stimuli and the resolution of inflammation by phagocytosis of apoptotic neutrophils. Preterm lambs at 124 d gestation were delivered 15 h, 1 d, 2 d, or 7 d after 0.5 mg/kg maternal intramuscular betamethasone. Monocytes from cord blood were isolated and cultured and results were compared with monocytes from preterm lambs exposed to maternal saline or monocytes from adult sheep. Phagocytosis of Escherichia coli was not changed, however, phagocytosis of apoptotic neutrophils was low in fetal monocytes but increased after 7 d exposure to maternal betamethasone to the level found in adult monocytes. Hydrogen peroxide production after endotoxin stimulus was significantly reduced to 7.1 +/- 2.2 micromol at 5 h, 8.7 +/- 2.9 micromol at 24 h, and 4.1 +/- 1.9 micromol at 48 h versus 16.4 +/- 3.6 micromol in control animals; at 7 d, the hydrogen peroxide production increased to 74.3 +/- 19.7 micromol (p < 0.05, per 10(6) monocytes). IL-6 production was reduced at 15 h after maternal betamethasone but at no other time point. Maternal betamethasone initially suppressed several fetal monocyte functions, however, at 7 d, measurements of initiation and resolution of inflammation were increased to levels similar to monocytes from adult sheep. The time-dependent changes in maternal betamethasone modulation of the responses of fetal monocytes may influence immune function of the preterm lamb after delivery.
Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14973182&dopt=Abstract betamethasone Diprolene AF
Diprolene AF (betamethasone) References
Diprolene AF or betamethasone 1 |
Diprolene AF or betamethasone 2 |
Diprolene AF or betamethasone 3 |
Diprolene AF or betamethasone 4 |
Diprolene AF or betamethasone 5 |
Diprolene AF or betamethasone 6 |
Diprolene AF or betamethasone 7 |
Diprolene AF or betamethasone 8 |
Diprolene AF or betamethasone 9 |
Diprolene AF or betamethasone 10 |
Diprolene AF or betamethasone 11 |
Diprolene AF or betamethasone 12 |
Diprolene AF or betamethasone 13 |
Diprolene AF or betamethasone 14 |
Diprolene AF or betamethasone 15 |
Diprolene AF or betamethasone 16 |
Diprolene AF or betamethasone 17 |
Diprolene AF or betamethasone 18 |
Diprolene AF or betamethasone 19 |
Diprolene AF or betamethasone 20 |
Diprolene AF or betamethasone 21 |
Diprolene AF or betamethasone 22 |
Diprolene AF or betamethasone 23 |
Diprolene AF or betamethasone 24 |
Diprolene AF or betamethasone 25 |
Diprolene AF or betamethasone 26 |
Diprolene AF or betamethasone 27 |
Diprolene AF or betamethasone 28 |
Diprolene AF or betamethasone 29 |
Diprolene AF or betamethasone 30 |
Diprolene AF or betamethasone 31 |
Diprolene AF or betamethasone 32 |
Diprolene AF or betamethasone 33 |
Diprolene AF or betamethasone 34 |
Diprolene AF or betamethasone 35 |
Diprolene AF or betamethasone 36 |
Diprolene AF or betamethasone 37 |
Diprolene AF or betamethasone 38 |
Diprolene AF or betamethasone 39 |
Diprolene AF or betamethasone 40 |
Diprolene AF or betamethasone 41 |
Diprolene AF or betamethasone 42 |
Diprolene AF or betamethasone 43 |
Diprolene AF or betamethasone 44 |
Diprolene AF or betamethasone 45
| |